Search

Your search keyword '"Katerina Paraskevaidou"' showing total 2 results
Start Over Author "Katerina Paraskevaidou" Topic 03 medical and health sciences
2 results on '"Katerina Paraskevaidou"'

1. Asthma and rhinitis in Greek furniture workers

Author

Theodoros Kontakiotis, Katerina Paraskevaidou, Dionisios Spyratos, Ioannis Kioumis, Konstantinos Porpodis, and Despina Papakosta

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Bronchial Provocation Tests, 03 medical and health sciences, 0302 clinical medicine, Occupational Exposure, Environmental health, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Rhinitis, Asthma, Air Pollutants, Greece, business.industry, Masks, Dust, Middle Aged, medicine.disease, Wood, Rhinomanometry, Ventilation, Respiratory Function Tests, Occupational Diseases, 030228 respiratory system, Pediatrics, Perinatology and Child Health, Female, Methacholine, business, Interior Design and Furnishings, medicine.drug
Abstract

Objective: The detection of asthma and rhinitis in furniture workers exposed to chemicals in the area of Thessaloniki Greece and the determination of the most useful tests for diagnosing the above ...

Published
2019
Full Text
View/download PDF

2. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

Author

Georgia Trakada, Aggeliki Rapti, Chrysanthi Sardeli, Anastasios Kallianos, Haidong Huang, Katerina Paraskevaidou, Panagiotis Chinelis, Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Anastasia Athanasiadou, and Lemonia Veletza

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Afatinib, Case Report, Adenocarcinoma, NSCLC, 03 medical and health sciences, T790M, 0302 clinical medicine, Gefitinib, Epidermal growth factor, Internal medicine, medicine, Osimertinib, 030212 general & internal medicine, Liquid biopsy, Erlotinib and afatinib, lcsh:RC705-779, business.industry, lcsh:Diseases of the respiratory system, respiratory tract diseases, 030220 oncology & carcinogenesis, Gefitinb, Cancer research, Erlotinib, business, Tyrosine kinase, medicine.drug
Abstract

Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erlotinib and afatinib dosage can be modified in the case of severe adverse effects. In the case of disease relapse investigation for T790M mutation has to be made either with re-biopsy or liquid biopsy and osimertinib has to be administered when T790M is diagnosed. Based on a case series we indicate which is the best approach for T790M mutation.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results